Development and Validation of Robust, Highly Sensitive and Stability-Indicating RP-HPLC Method for Estimation of Deferasirox and its Degradation Products

• Published in: Journal of chromatographic science 2024-10, Vol.62 (8), p.709-718
• Main Authors: Shishodia, Tarun, Grover, Parul, Nagarajan, K, Bhardwaj, Monika, Chopra, Bhawna
• Format: Article
• Language: English
• Subjects: Chromatography, High Pressure Liquid - methods; Chromatography, Reverse-Phase - methods; Deferasirox - analysis; Deferasirox - chemistry; Drug Stability; Limit of Detection; Linear Models; Reproducibility of Results; Triazoles - analysis; Triazoles - chemistry
• ISSN: 0021-9665; 1945-239X; 1945-239X
• DOI: 10.1093/chromsci/bmad032

Abstract A rapid, simple and highly sensitive stability-indicating reverse-phase high-performance liquid chromatographic technique, coupled with a photodiode array detector, was developed and validated for the estimation of Deferasirox (DFS). The chromatographic separation was achieved using a C-18 (250 × 4.6 mm, 5 μm) stationary phase and a mobile phase composed of 0.1% orthophosphoric acid and acetonitrile at a flow rate of 1 mL/min. The detection was carried out at a wavelength of 245 nm with a constant injection volume of 10 μL throughout the analysis. With an R2 value of 0.9996, the calibration curve was determined to be linear over an appropriate concentration range of 50–500 ng/mL. According to the International Conference on Harmonization (ICH) Q1 (R2) guideline, DFS was evaluated under stress conditions that included hydrolytic (acid, alkali and neutral), oxidative and thermal degradation. The findings demonstrated that significant degradation was observed in acidic degradation conditions, whereas drug substance was found to be stable when exposed to neutral, basic, oxidative and thermal degradation. The developed method was validated as per ICH guidelines. The developed method was employed successfully to estimate the amount of DFS in bulk and pharmaceutical formulation.